Status: retired, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2020. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 2662930013 | Haemophilus influenzae type b 10micrograms/diphtheria toxoid 30 iu/tetanus toxoid 40 iu/pertussis 25micrograms/recombinant hepatitis B virus surface antigen 10micrograms/inactivated poliomyelitis injection solution 0.5mL prefilled syringe (product) | en | Fully specified name | Active | Entire term case sensitive (core metadata concept) | SNOMED CT core |
| 2674863017 | Haemophilus influenzae type b 10micrograms/diphtheria toxoid 30 iu/tetanus toxoid 40 iu/pertussis 25micrograms/recombinant hepatitis B virus surface antigen 10micrograms/inactivated poliomyelitis injection solution 0.5mL prefilled syringe | en | Synonym (core metadata concept) | Active | Entire term case sensitive (core metadata concept) | SNOMED CT core |
| 4731831000005115 | Haemophilus influenzae type b-vaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + kighostevaccine 25 µg + rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + inaktiveret poliovaccine injektionsvæske, opløsning 0,5 ml i fyldt sprøjte | da | Synonym (core metadata concept) | Active | Entire term case sensitive (core metadata concept) | Danish module (core metadata concept) |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Haemophilus influenzae type b-vaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + kighostevaccine 25 µg + rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + inaktiveret poliovaccine injektionsvæske, opløsning 0,5 ml i fyldt sprøjte | Is a | difteri- + tetanus- + kighoste- + polio- + rekombinant hepatitis B-virus- + rekombinant Haemophilus influenzae type b-vaccine | false | Inferred relationship | Some | ||
| Haemophilus influenzae type b-vaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + kighostevaccine 25 µg + rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + inaktiveret poliovaccine injektionsvæske, opløsning 0,5 ml i fyldt sprøjte | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | rekombinant vaccine mod hepatitis B-virus | false | Inferred relationship | Some | ||
| Haemophilus influenzae type b-vaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + kighostevaccine 25 µg + rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + inaktiveret poliovaccine injektionsvæske, opløsning 0,5 ml i fyldt sprøjte | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | difterivaccine | false | Inferred relationship | Some | ||
| Haemophilus influenzae type b-vaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + kighostevaccine 25 µg + rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + inaktiveret poliovaccine injektionsvæske, opløsning 0,5 ml i fyldt sprøjte | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | kighostevaccine | false | Inferred relationship | Some | ||
| Haemophilus influenzae type b-vaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + kighostevaccine 25 µg + rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + inaktiveret poliovaccine injektionsvæske, opløsning 0,5 ml i fyldt sprøjte | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | tetanustoxoid | false | Inferred relationship | Some | ||
| Haemophilus influenzae type b-vaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + kighostevaccine 25 µg + rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + inaktiveret poliovaccine injektionsvæske, opløsning 0,5 ml i fyldt sprøjte | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | vaccine mod Haemophilus influenzae type B | false | Inferred relationship | Some | ||
| Haemophilus influenzae type b-vaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + kighostevaccine 25 µg + rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + inaktiveret poliovaccine injektionsvæske, opløsning 0,5 ml i fyldt sprøjte | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | inaktiveret poliovirusvaccine | false | Inferred relationship | Some | ||
| Haemophilus influenzae type b-vaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + kighostevaccine 25 µg + rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + inaktiveret poliovaccine injektionsvæske, opløsning 0,5 ml i fyldt sprøjte | Has manufactured dose form | injektionsvæske | false | Inferred relationship | Some | ||
| Haemophilus influenzae type b-vaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + kighostevaccine 25 µg + rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + inaktiveret poliovaccine injektionsvæske, opløsning 0,5 ml i fyldt sprøjte | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Diphtheria vaccine | false | Inferred relationship | Some | ||
| Haemophilus influenzae type b-vaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + kighostevaccine 25 µg + rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + inaktiveret poliovaccine injektionsvæske, opløsning 0,5 ml i fyldt sprøjte | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | tetanusvaccine | false | Inferred relationship | Some | ||
| Haemophilus influenzae type b-vaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + kighostevaccine 25 µg + rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + inaktiveret poliovaccine injektionsvæske, opløsning 0,5 ml i fyldt sprøjte | Is a | Product manufactured as parenteral dose form (product) | false | Inferred relationship | Some | ||
| Haemophilus influenzae type b-vaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + kighostevaccine 25 µg + rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + inaktiveret poliovaccine injektionsvæske, opløsning 0,5 ml i fyldt sprøjte | Has manufactured dose form | Solution for injection | false | Inferred relationship | Some | ||
| Haemophilus influenzae type b-vaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + kighostevaccine 25 µg + rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + inaktiveret poliovaccine injektionsvæske, opløsning 0,5 ml i fyldt sprøjte | Is a | TEMPORARY parent for CDs that are not updated | false | Inferred relationship | Some | ||
| Haemophilus influenzae type b-vaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + kighostevaccine 25 µg + rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + inaktiveret poliovaccine injektionsvæske, opløsning 0,5 ml i fyldt sprøjte | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Diphtheria vaccine | false | Inferred relationship | Some | 5 | |
| Haemophilus influenzae type b-vaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + kighostevaccine 25 µg + rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + inaktiveret poliovaccine injektionsvæske, opløsning 0,5 ml i fyldt sprøjte | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | kighostevaccine | false | Inferred relationship | Some | 3 | |
| Haemophilus influenzae type b-vaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + kighostevaccine 25 µg + rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + inaktiveret poliovaccine injektionsvæske, opløsning 0,5 ml i fyldt sprøjte | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | inaktiveret poliovirusvaccine | false | Inferred relationship | Some | 4 | |
| Haemophilus influenzae type b-vaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + kighostevaccine 25 µg + rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + inaktiveret poliovaccine injektionsvæske, opløsning 0,5 ml i fyldt sprøjte | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | vaccine mod Haemophilus influenzae type B | false | Inferred relationship | Some | 1 | |
| Haemophilus influenzae type b-vaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + kighostevaccine 25 µg + rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + inaktiveret poliovaccine injektionsvæske, opløsning 0,5 ml i fyldt sprøjte | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | rekombinant vaccine mod hepatitis B-virus | false | Inferred relationship | Some | 6 | |
| Haemophilus influenzae type b-vaccine 10 µg + difteritoxoid 30 IE + tetanustoxoid 40 IE + kighostevaccine 25 µg + rekombinant hepatitis B-virusoverfladeantigenvaccine 10 µg + inaktiveret poliovaccine injektionsvæske, opløsning 0,5 ml i fyldt sprøjte | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | tetanusvaccine | false | Inferred relationship | Some | 2 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets
Concept inactivation indicator reference set
POSSIBLY EQUIVALENT TO association reference set (foundation metadata concept)
FHIR